Colossal Biosciences is thrilled to announce a major funding milestone, securing $50 million in its latest financing round. This breakthrough bioscience and genetic engineering company is at the forefront of pioneering radical new technologies that are reshaping the landscape of genomics. With a mission centered on the science of genetics and the business of discovery, Colossal Biosciences has been recognized as an innovator in the conservation arena, notably becoming the first organization to utilize CRISPR technology for species de-extinction. As it embarks on its ambitious journey to bring back the woolly mammoth, the company also addresses critical issues surrounding the protection of severely endangered species and the restoration of pivotal ecosystems that are vital for sustaining life on Earth. The recent funding will play a crucial role in advancing Colossal鈥檚 technologies, enabling further research and development in genetic restoration and ecological preservation. This capital infusion not only strengthens the company鈥檚 dedication to its revolutionary objectives but also reflects growing investor confidence in the potential of biotechnology to tackle some of the most pressing environmental challenges we face today. As Colossal embraces humanity鈥檚 responsibility to restore our planet to a healthier state, the company continues to find innovative solutions that intertwine cutting-edge science with the essential economic and biological needs of the human condition. With this substantial backing, Colossal is well-poised to make significant strides towards a sustainable future.





